Abbott Laboratories has posted strong sales and earnings growth for the fourth quarter, driven again by its anti-inflammatory blockbuster Humira.
Net income was up 12.3% to $1.62 billion, while group sales increased 4.1% to $10.38 billion. Pharmaceutical revenues climbed 6.7% to $4.78 billion and Humira (adalimumab), which is approved for indications covering rheumatoid arthritis, Crohn’s disease and psoriasis, contributed $2.18 billion (+15.9%).
As for the company’s lipids franchise, TriCor (fenofibrate) and TriLipix (fenofibric acid) had sales of $409 million, down 4.3%, while Niaspan (niacin) brought in $258 million, a decrease of 10%. Of Abbott’s other products, the prostate cancer therapy Lupron (leuprolide) rose 4.0% to $208 million, while revenues from the HIV drug Kaletra (lopinavir/ritonavir) were down 15.6% to $288 million. Sales of the hypothyroid medication Synthroid (levothyroxine) were up 2.0% to $163 million.
Abbott's nutritional products had sales of $1.56 million, up 8.6%, while 'established pharmaceuticals', which includes sales of branded generics outside the USA, fell 4.6% to $1.39 billion. Fourth-quarter sales of vascular products, which includes heart stents, inched up 0.6% to $826 million.
Chief executive Miles White said that "despite another challenging year for the global economy, Abbott again delivered leading performance, including strong sales and ongoing earnings-per-share growth". He added that the plan , announced in October, to split off Abbott's $18 billion drugs arm from the diagnostics, devices, nutrition and branded generics businesses, should be completed by the end of the year.
Analysts were a little disappointed with the figures and Rick Wise at Leerink Swann issued a research a note, saying that pharmaceutical sales were $100 million less than expected, but that was due principally to the effects of foreign exchange.
The views expressed in the following comments are not those of PharmaTimes or any connected third party and belong specifically to the individual who made that comment. We accept no liability for the comments made and always advise users to exercise caution.